Dominique Valteau‐Couanet

Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma

Isabelle Janoueix‐Lerosey, Delphine Lequin, Laurence Brugières et al. · Nature · 2008 · 887 citations

Somatic Variant, Receptor Tyrosine Kinase, Alk Kinase Receptor +5

Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial

Ruth Ladenstein, Ulrike Pötschger, Dominique Valteau‐Couanet et al. · The Lancet Oncology · 2018 · 379 citations

Interleukin 2, Autoimmune Disease, Anti-gd2 Antibody Ch14.18/cho +7

Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial

Selim Corbacioglu, Simone Cesaro, Maura Faraci et al. · The Lancet · 2012 · 372 citations

Transplantation, Hepatology, Hepatic Veno-occlusive Disease +8

Overall Genomic Pattern Is a Predictor of Outcome in Neuroblastoma

Isabelle Janoueix‐Lerosey, Gudrun Schleiermacher, Evi Michels et al. · Journal of Clinical Oncology · 2009 · 345 citations · Full text

Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial

Ruth Ladenstein, Ulrike Pötschger, Andrew D.J. Pearson et al. · The Lancet Oncology · 2017 · 334 citations · Full text

Oncology, Medicine, Versus Carboplatin +8